- US11951097utility2024Methods of Treating Multiple Sclerosis0 cites
- US11918556utility2024Treatment of Circadian Rhythm Disorders0 cites
- US11918557utility2024Treatment of Circadian Rhythm Disorders0 cites
- US11850229utility2023Treatment of Circadian Rhythm Disorders0 cites
- US11845990utility2023Prediction of Sleep Parameter and Response to Sleep-inducing Compound Based on PER3 VNTR Genotype0 cites
- US11833130utility2023Treatment of Circadian Rhythm Disorders0 cites
- US11826339utility2023Treatment of Circadian Rhythm Disorders0 cites
- US11786502utility2023Method of Treatment0 cites
- US11759446utility2023Liquid Tasimelteon Formulations and Methods of Use Thereof0 cites
- US11760740utility2023Highly Purified Pharmaceutical Grade Tasimelteon0 cites
- US11737993utility2023Multiple Myeloma Treatment0 cites
- US11723903utility2023Treatment of Schizophrenia0 cites
- US11667718utility2023Cancer Treatment0 cites
- US11633377utility2023Treatment of Circadian Rhythm Disorders0 cites
- US11607408utility2023Method of Treatment of Schizophrenia0 cites
- US11566011utility2023Highly Purified Pharmaceutical Grade Tasimelteon0 cites
- US11549147utility2023Treatment of Atopic Dermatitis with Tradipitant0 cites
← PreviousPage 2 of 2